Triple Infections With Campylobacter coli, Cytomegalovirus, and SARS-CoV-2 in a Lymphoma Patient Treated With Epcoritamab - PubMed
3 hours ago
- #epcoritamab
- #lymphoma
- #immunocompromised
- A lymphoma patient treated with epcoritamab developed triple infections: Campylobacter coli, Cytomegalovirus, and SARS-CoV-2.
- Epcoritamab, a novel B-cell targeting therapy, led to B-cell depletion, increasing infection susceptibility.
- The patient required oxygen therapy for COVID-19 pneumonia and treatment for bloodstream infection and Cytomegalovirus antigenemia.
- Infections were managed with remdesivir, meropenem, and ganciclovir, leading to recovery but prolonged SARS-CoV-2 shedding.
- The case highlights the need for vigilance in patients undergoing B-cell manipulating therapies like epcoritamab, CAR-T, and BiTEs.